Cell Source focuses on developing cell therapy treatments based on the management of immune tolerance.
Cell Source has raised $1.5M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in January 2026.
Cell Source is headquartered in New York, United States.
Cell Source focuses on developing cell therapy treatments based on the management of immune tolerance.
Cell Source is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cell Source — Funding & Investors." VCBacked, January 15, 2026, https://www.vcbacked.co/company/cell-source. Accessed August 17, 2026.
VCBacked. (2026). Cell Source — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/cell-source
{{cite web |title=Cell Source — Funding & Investors |url=https://www.vcbacked.co/company/cell-source |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated